Review of Biologics in Children With Rheumatic Diseases

Shabina Habibi; Athimalaipet V Ramanan


Int J Clin Rheumatol. 2012;7(1):81-93. 

In This Article

Future Perspective

Research over the next few years will focus on understanding the pathogenesis of the various juvenile rheumatic diseases more thoroughly, and better defining the various cytokines and small molecules involved. Efficacy of small-molecule inhibitors, which have the major advantage of being orally administered, and are currently being studied in rheumatoid arthritis, will be studied in JIA. There will be more large-scale registries available to fully understand the as yet unknown side effects. Collaborative efforts, especially between the developing nations and the west will be a major step forward. Studies on the withdrawal of biologics and the rates of sustained remission of drugs will be needed. Finally, pharmacogenomics will help in more accurately predicting those children who will respond to a particular biologic, require long-term medication or develop major side effects due to a particular drug.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: